Glassman Robert sold $300K of PHVS
Glassman Robert sold 8,000 shares of Pharvaris N.V. (PHVS) at $37.55 ($0.30M total) on 2026-09-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The director's sale is modest and pre‑arranged, offering limited actionable insight.
Market read
Minor insider sell; low trading relevance.
What to watch
Potential upcoming clinical data or financing needs not disclosed.
Background
SEC Form 4 filing discloses insider transactions; required for transparency.
Ticker impact
Director Robert Glassman sold 8,000 shares for $300,396 via a 10b5-1 plan, reducing his stake to 10,500 shares.
Small downward pressure, but unlikely to move the stock materially.
The sale amount is modest relative to market cap and follows a pre‑arranged plan, suggesting no urgent signal.
Market effects
No broader sector impact; typical insider sale for a small biotech.
Limited to US biotech investors.
Minimal.
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanyPharvaris N.V.
Biotech firm listed on Nasdaq under ticker PHVS.
- IndividualRobert Glassman
Director of Pharvaris who executed the sale.
